
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

Lead Product(s) : Neostigmine
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Intestinal Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Neostigmine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Neostigmine
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2017
Lead Product(s) : Neostigmine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Neostigmine
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuromuscular Blockade.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2017
Lead Product(s) : Neostigmine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Neostigmine
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Melbourne Health | Peter MacCallum Cancer Centre | Royal Hospital For Women | Northpark Private Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Deep Neuromuscular Block for Laparoscopic Surgery
Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2017
Lead Product(s) : Neostigmine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Melbourne Health | Peter MacCallum Cancer Centre | Royal Hospital For Women | Northpark Private Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Neostigmine
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Quality of Recovery After Reversal With Neostigmine or Sugammadex.
Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuromuscular Blockade.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2016
Lead Product(s) : Neostigmine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Neostigmine
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neostigmine Reversal And Neuromuscular Recovery
Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2015
Lead Product(s) : Neostigmine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All